Béa Fertility, a pioneering fertility tech startup making clinical-grade fertility care available at home, has raised €2.9 million to release its first groundbreaking at-home fertility treatment to early adopters in the UK. The round was led by Octopus Ventures and joined by JamJar and Forward Partners, with additional participation from existing investors Calm/Storm and Q Ventures. This raise brings Béa Fertility’s total funding to date to €3.8 million. Béa will join companies including Elvie and Mojo in Octopus Ventures’ portfolio.
This new injection of funding is being used to make the first Béa Treatment Kits available to the public. The first Béa treatment is available to purchase online via Béa’s website now. The first users to purchase a kit will pay just £350 for three ICI treatment cycles, with one Treatment Kit delivered at the beginning of each menstrual cycle throughout the three-month treatment program. The program is targeted at users currently trying to conceive.
Led by femtech expert Tess Cosad and product engineer George Thomas, this healthtech founded in 2020 has developed one of the first clinical-grade at-home fertility treatments ever to launch in the UK market. The first Béa Fertility Treatment Kit enables users to carry out a simple fertility treatment called Intracervical Insemination (ICI) safely at home. The treatment is creating a revolutionary new stepping stone on the fertility pathway that can be explored in advance of costly and invasive procedures like IVF and Intrauterine Insemination (IUI).
Béa’s aim is to make a transformative and inclusive new fertility offering available to people who are struggling to conceive, with a focus on widening access to care for LGBTQ families and groups traditionally excluded from existing fertility provision.
Tess Cosad, CEO and co-founder at Béa Fertility, commented: “Fertility impacts 1 in 6 couples, yet access to fertility care is severely lacking globally. Fertility clinics have been selling the same expensive treatments for decades, yet there are a number of groups which remain underserved, including the LGBTQIA+ community, single people and parents experiencing secondary infertility. At Béa, our aim is to fill this gap by creating inclusive, clinical-grade fertility treatments that can be used at home. This latest injection of funding – from experienced investors with a proven track record of backing successful fertility and femtech businesses – will enable us to get our pioneering treatment in the hands of the people who need it most. We can’t wait for people to try it.”
The first people to purchase a Treatment Kit and join the Béa community will be contributing to the world’s largest at-home fertility treatment study. During this initial treatment roll-out, Béa will be collecting observational and efficacy data to close the data gap surrounding infertility. Over 1,000 people have already signed up to take part. The study aims to drive advancements in the development of early-stage fertility interventions and accelerate Béa’s mission to build accessible fertility treatments for all. The early results of the study will be presented at the IFFS World Congress in Athens later this year.
Kirsten Connell, Investor at Octopus Ventures, said: “At Octopus Ventures we back founders who are changing the world for the better. We invest where we can make the greatest positive impact. When it comes to starting a family there are few things in life more meaningful than this. Béa Fertility who is reimagining the fertility care pathway, was a clear vision we wanted to get behind. We’re delighted to have joined Tess and her team on this journey.”
Brian Hatton, Partner at Q Ventures, added: “We backed Tess and the Béa team at the idea stage in their 2021 pre-seed round and they have made incredible progress since. Their at home product is truly a groundbreaking new step in the fertility care pathway, and we are excited to continue to support this incredible group as they launch and scale.”